# Shufang Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shufang-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Yangzhou, China
- Latest round: Angel (Jun 4, 2025)
- Investors on record: 3

## About

Established in 2024 and based in Yangzhou, China, Shufang Pharmaceutical operates as a rare disease drug developer that mainly provides new drugs.  The company focuses on the research and development and commercialization of drugs for rare diseases. Its products include Anjali® (valmorolone oral suspension) and eriglitazone (MIN-102). Anjali is used to treat patients with Duchenne muscular dystrophy (DMD) aged four years and above. Shufang Pharmaceutical is also engaged in drug contract manufacturing, drug import and export, and drug wholesale. The company generates revenue by providing drugs for rare diseases. In June 2025, the company closed venture funding from new investors Lilly Asia Ventures, Prosperico Ventures, and Dingxin Venture Capital.

## Funding rounds

- Angel, Jun 4, 2025 — Lilly Asia Ventures, Prosperico Ventures, Dingxin Venture Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Angel
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Angel
- Dingxin Venture Capital — Angel